|1.||Adeyi, Ben: 15 articles (12/2014 - 01/2010)|
|2.||Dirks, Bryan: 15 articles (12/2014 - 12/2010)|
|3.||Gao, Joseph: 11 articles (12/2014 - 10/2009)|
|4.||Gasior, Maria: 11 articles (12/2014 - 01/2010)|
|5.||Findling, Robert L: 11 articles (05/2014 - 03/2007)|
|6.||Scheckner, Brian: 11 articles (08/2013 - 12/2010)|
|7.||Lasser, Robert: 10 articles (05/2014 - 12/2010)|
|8.||Babcock, Thomas: 10 articles (08/2013 - 12/2010)|
|9.||Banaschewski, Tobias: 8 articles (12/2014 - 09/2013)|
|10.||Childress, Ann C: 8 articles (05/2014 - 07/2008)|
|1.||Attention Deficit Disorder with Hyperactivity (Attention Deficit Hyperactivity Disorder)
02/01/2011 - "Changes in Attention Deficit Hyperactivity Disorder Rating Scale IV total scores and Clinical Global Impressions-Improvement scale were used to evaluate the efficacy of lisdexamfetamine dimesylate. "
12/01/2014 - "The stimulant prodrug lisdexamfetamine dimesylate (LDX) is an effective and generally well tolerated treatment for the symptoms of attention-deficit/hyperactivity disorder (ADHD). "
05/01/2012 - "Lisdexamfetamine dimesylate was effective in participants with predominantly inattention, hyperactivity/ impulsivity, and combined attention deficit hyperactivity disorder symptom clusters. "
06/01/2014 - "In this phase 3 extension study, the long-term maintenance of efficacy of lisdexamfetamine dimesylate (LDX) in children and adolescents with attention-deficit/hyperactivity disorder (ADHD) was evaluated using a randomized-withdrawal study design. "
06/01/2014 - "Maintenance of efficacy of lisdexamfetamine dimesylate in children and adolescents with attention-deficit/hyperactivity disorder: randomized-withdrawal study design."
|2.||Major Depressive Disorder (Major Depressive Disorders)
05/01/2014 - "Lisdexamfetamine dimesylate augmentation in adults with persistent executive dysfunction after partial or full remission of major depressive disorder."
05/01/2014 - "Evaluate lisdexamfetamine dimesylate (LDX) augmentation of antidepressant monotherapy for executive dysfunction in partially or fully remitted major depressive disorder (MDD). "
08/01/2013 - "Evaluate the efficacy and safety of lisdexamfetamine dimesylate augmentation for major depressive disorder (MDD) in escitalopram nonremitters. "
08/01/2013 - "A randomized controlled trial of the efficacy and safety of lisdexamfetamine dimesylate as augmentation therapy in adults with residual symptoms of major depressive disorder after treatment with escitalopram."
04/01/2013 - "Lisdexamfetamine dimesylate (LDX), a prodrug consisting of d-amphetamine and l-lysine, is being studied in clinical trials of major depressive disorder. "
|3.||Chronic Fatigue Syndrome (Myalgic Encephalomyelitis)
05/15/2013 - "The purpose of this study was to assess the efficacy of lisdexamfetamine dimesylate (LDX) for the treatment of executive functioning deficits in adults (ages 18-60) with chronic fatigue syndrome (CFS). "
05/15/2013 - "Use of lisdexamfetamine dimesylate in treatment of executive functioning deficits and chronic fatigue syndrome: a double blind, placebo-controlled study."
|4.||Schizophrenia (Dementia Praecox)
12/01/2014 - "Safety and pharmacokinetics of lisdexamfetamine dimesylate in adults with clinically stable schizophrenia: a randomized, double-blind, placebo-controlled trial of ascending multiple doses."
10/01/2013 - "Adjunctive lisdexamfetamine dimesylate therapy in adult outpatients with predominant negative symptoms of schizophrenia: open-label and randomized-withdrawal phases."
12/01/2014 - "To assess the safety and pharmacokinetics of lisdexamfetamine dimesylate (LDX), a d-amphetamine prodrug, this double-blind study enrolled adults with clinically stable schizophrenia who were adherent (≥12 weeks) to antipsychotic pharmacotherapy. "
10/01/2013 - "This multicenter study examined lisdexamfetamine dimesylate (LDX), a d-amphetamine prodrug, as adjunctive therapy to antipsychotics in adults with clinically stable schizophrenia and predominant NSS. "
10/01/2014 - "In a study of acute sleep deprivation in healthy male volunteers randomized to double-blind treatment with lisdexamfetamine dimesylate (20, 50, or 70 mg), placebo control, or an active control (armodafinil 250 mg), Maintenance of Wakefulness Test data were compared using a generalized estimating equation analysis to eliminate the need for unequivocal sleep latency imputation. "
|1.||Drug Therapy (Chemotherapy)